UCH-L1/PGP9.5 Antibody

UCH-L1 (ubiquitin carboxyl-terminal hydrolase isozyme L1) was the first discovered de-ubiquitinating enzyme which implicates in processing of ubiquitin precursors and also of ubiquitinated proteins. UCH-L1 is a thiol protease that recognizes and hydrolyzes a peptide bond at C-terminal glycine of ubiquitin. It also binds to free monoubiquitin and prevents its degradation in lysosomes. Localized in cytoplasm and ER membrane as lipid-anchor, UCH-L1 expression is restricted to brain, peripheral nerves, endocrine tissues and gonads of both sexes etc. UCH-L1 deletion in mice leads to fatal neurodegenerative disorder known as gracile axonal dystrophy and it is down-regulated in brains from Parkinson as well as Alzheimer disease patients. Expression outside of neuro-endocrine tissues is found in various cancers including B-cell lymphoma, multiple myeloma, and lung cancer. In transgenic mouse model, UCH-L1 has been demonstrated as an oncogene that causes malignancies by boosting AKT signalling. Furthermore, UCH-L1 has been shown to interfere with ubiquitination of RAPTOR which is catalyzed by DDB1-Cul4 E3 ligase complex, leading to loss of mTORC1 integrity accompanied by a concurrent increase in mTORC2, likely due to increased availability of free mTOR.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: IHC-Fr, WB.

Showing Publications 1 - 3 of 3.

Publications using NB300-676	Applications	Species
Awad-Igbaria Y, Dadon S, Shamir A et al. Characterization of Early Inflammatory Events Leading to Provoked Vulvodynia Development in Rats Journal of inflammation research 2022-07-11 [PMID: 35845089]
Powis RA, Mutsaers CA, Wishart TM et al. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target. Neuropathol. Appl. Neurobiol. 2014-07-08 [PMID: 25041530] (IHC-Fr, WB, Mouse, Human) Details: UCHL-1 antibody used for WB (1:2000 dilution) and IHC-Fr (1:500 dilution) - see full text for detailed methods. WB performed on Type I SMA patient primary fibroblasts (Figure 1), ‘Taiwanese’ SMA mouse spinal cord and skeletal (Figure 2) and E17 rat hippocampal neurons treated or not with 50uM UBEI-41, a cell-permeable ubiquitin E1 inhibitor muscle (Figure 7). IHC was done on frozen sections of ventral horn of the spinal cord and gastrocnemius muscle of ‘Taiwanese’ SMA mouse (Figure 2 C and F).	IHC-Fr, WB	Mouse, Human
Wang R, Zhang M, Zhou W et al. NF-kappaB signaling inhibits ubiquitin carboxyl-terminal hydrolase L1 gene expression. J Neurochem 2011-03-01 [PMID: 21104237] (WB, Human)	WB	Human

Images	Ratings	Applications	Species	Date	Details
Enlarge	3 reviewed by: Verified Customer	IHC-Fr	Human	11/25/2015	View Summary Application Immunohistochemistry-Frozen Sample Tested human skin, 60micron thick section for confocal immunofluorescent imaging Species Human Lot A-1

Array NB300-676

• UCH-L1/PGP9.5 Antibodies
• UCH-L1/PGP9.5 Lysate
• UCH-L1/PGP9.5 Proteins
• UCH-L1/PGP9.5 ELISA
• UCH-L1/PGP9.5 Proteins and Enzyme